又有两款国际创新药获批国内上市

Core Insights - Two international innovative drugs, Inclisiran sodium injection (new indication) and Ruxolitinib cream, have recently received approval for domestic market entry in China, supported by real-world data research from Hainan [2] Group 1: Drug Approvals - Inclisiran sodium injection is the world's first and only small interfering RNA drug targeting PCSK9 for cholesterol reduction, offering a "two injections a year" treatment plan for patients with hypercholesterolemia, which is expected to improve medication adherence and long-term lipid control rates [2] - Ruxolitinib cream is the first and only JAK inhibitor approved for localized treatment of vitiligo, which has already benefited nearly 10,000 patients since its emergency use approval in August 2023, filling a long-standing gap in targeted local therapies for this condition [2] Group 2: Market Impact - A total of 24 international innovative drugs and devices have been accelerated for domestic approval through this pathway, indicating a growing trend in the Chinese pharmaceutical market towards faster access to innovative treatments [2] - Ruxolitinib cream is advancing towards local registration in Hainan, with the potential for local production in Haikou National High-tech Zone by 2027, which could further benefit a larger patient population [2]